Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.54 |
| ▸ | FBP1 | P09467 | 2/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15653322 | 0.74 | RAB9A (0.49) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL3090628 | 0.73 | PDK1 (0.56) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL7325816 | 0.73 | APOBEC3A (0.61) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL12210600 | 0.71 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL558522 | 0.71 | APOBEC3A (0.95) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL2749715 | 0.71 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL10965367 | 0.71 | APOBEC3A (0.59) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL17028600 | 0.71 | APOBEC3A (0.59) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL171200 | 0.71 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL8003326 | 0.70 | PDK1 (0.47) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| US-7601846-B2 | Compounds having activity as inhibitors of apoptosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PDK1 507/4885FBP1 330/4885APOBEC3A 4649/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PDK1 507/4885FBP1 330/4885APOBEC3A 4649/4885 |
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | BAD, CASP3, BAX | PDK1 784/4885FBP1 695/4885APOBEC3A 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.